Summit Therapeutics (SMMT) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.28
- EPS estimate
- −$0.27
- EPS surprise
- −2.04%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Jul 23, 2026
Summit Therapeutics reported a Q2 2026 loss of $0.28 per share on July 23, 2026. That was 2.04% wider than the estimate of a $0.27 loss. The table gives no revenue figure or revenue estimate for the quarter. A year earlier, Q2 2025 showed a loss of $0.76 per share, so the loss narrowed by about 63%. The table has no row for Q1 2026.
Every quarter in the table is a loss. Annual losses were $0.96 per share in 2021, $0.60 in 2022, $0.27 in 2024 and $1.45 in 2025. Quarterly losses stayed between $0.05 and $0.09 from Q4 2023 through Q1 2025, then widened to $0.76 in Q2 2025. The largest loss in the table was $1.43 in Q1 2023. The last reported revenue was $5,000, for Q4 2022. Over 20 quarters, results came in better than the estimate nine times and worse eight times.
Q3 results came out on October 20, 2025 and October 30, 2024, and in November in 2021 and 2022. That points to late October to mid-November 2026 for the next report. It will show whether the quarterly loss stays near the $0.28 to $0.31 per share of the last three reported quarters.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 23, 2026 | −$0.27 | −$0.28 | −2.04% | $0.00 | SEC |
| Q4 2025 | Feb 23, 2026 | −$0.09 | −$0.29 | −233.72% | $0.00 | SEC |
| Q3 2025 | Oct 20, 2025 | −$0.17 | −$0.31 | −82.25% | $0.00 | SEC |
| Q2 2025 | Aug 11, 2025 | −$0.09 | −$0.76 | −737.00% | $0.00 | SEC |
| Q1 2025 | May 1, 2025 | −$0.09 | −$0.09 | +3.23% | $0.00 | SEC |
| Q4 2024 | Feb 24, 2025 | −$0.08 | −$0.08 | +2.20% | $0.00 | SEC |
| Q3 2024 | Oct 30, 2024 | −$0.07 | −$0.08 | −19.76% | $0.00 | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.06 | −$0.05 | +19.22% | $0.00 | SEC |
| Q1 2024 | May 1, 2024 | −$0.06 | −$0.06 | +0.00% | $0.00 | SEC |
| Q4 2023 | Feb 20, 2024 | $0.00 | −$0.05 | +0.00% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | $0.00 | −$1.43 | +0.00% | $0.00 | SEC |
| Q4 2022 | Mar 9, 2023 | −$0.26 | −$0.07 | +73.08% | $5,000.00 | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.26 | −$0.14 | +46.15% | $220,000.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$0.27 | −$0.17 | +37.04% | $235,000.00 | SEC |
| Q1 2022 | May 11, 2022 | −$0.28 | −$0.22 | +21.43% | $250,000.00 | SEC |
| Q4 2021 | Mar 17, 2022 | −$0.27 | −$0.28 | −3.70% | $251,000.00 | SEC |
| Q3 2021 | Nov 15, 2021 | −$0.29 | −$0.20 | +31.03% | $1.3M | SEC |
| Q2 2021 | Aug 11, 2021 | −$0.18 | −$0.27 | −50.00% | $57,000.00 | — |
| Q1 2021 | May 17, 2021 | −$0.17 | −$0.21 | −23.53% | $192,000.00 | SEC |
| Q4 2020 | Mar 17, 2021 | −$0.21 | −$0.18 | +14.29% | $185,000.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Summit Therapeutics (SMMT) last report earnings?
Summit Therapeutics last reported on Jul 23, 2026, covering fiscal Q2 2026.
Did SMMT beat earnings estimates?
No. Summit Therapeutics reported EPS of −$0.28 for Q2 2026 against a −$0.27 estimate — a 2.04% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.